Samsung Bioepis is a biopharmaceutical company that develops and manufactures biosimilars.  The company's focus is on developing high-quality, affordable biosimilar medicines.

Samsung Bioepis

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.

Metric
Company Name	Samsung Bioepis	ALTEOGEN Inc.
Symbol		196.17K
MSH ID	COM:SAMSUNGBIOEPIS	COM:ALTEOGEN
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Biotechnology
Country	KR	KR
Stage
Employee Count		128
Website	samsungbioepis.com	alteogen.com
LinkedIn
Founders

Metric
Market Cap		10.06B
Enterprise Value
Monthly Web Traffic		6.86K
Web Traffic Growth		3.92
Valuation
Raised Capital

Metric
Revenue		67.81M
Revenue (LTM)
Revenue (NTM)
Gross Profit		57.77M
EBITDA		-4.50M
Operating Income		-6.84M
Net Income		-2.37M
EPS		-0.05
Diluted EPS		-0.05
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.52
Operating Profit Margin		0.15
EBITDA Margin		-0.07
Net Profit Margin		0.21
Return on Equity		0.16
Return on Assets		0.09
Return on Capital Employed		0.10

SAMS

COM:SAMSUNGBIOEPIS

Samsung Bioepis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		644.81
P/B Ratio		16.44
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		231.14
EV Multiple		799.93

Metric
Days Sales Outstanding		26.04
Days Payables Outstanding		3.63
Days Inventory Outstanding		5.90
Operating Cycle		126.15
Cash Conversion Cycle		120.56
Asset Turnover		0.44

Metric
Operating Cash Flow		-5.46M
Free Cash Flow		-35.98M
Cash Flow to Debt		0.36
Operating Cash Flow/Sales		0.26
Free Cash Flow Yield		-0.00

Metric
Cash & Equivalents		21.22M
Accounts Receivable		-4.92M
Inventory		750.56K
Goodwill		79.37K
Debt to Capitalization		0.36
Debt to Assets		0.01
Current Ratio		6.52
Quick Ratio		1.67

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.03
R&D to Revenue		0.25
SG&A to Revenue		0.01